Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-10

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of:

1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and
2. ClariLight Influenza A/B \& RSV test kits, for the qualitative detection and differential diagnosis of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) present in anterior nasal and oropharyngeal swab, in combination with an automated molecular diagnostic analyzer and sample collection tube by comparing them against a CE marked, in-vitro diagnostic device, used in the standard of care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites

NCT05728970

SARS-CoV-2 Influenza A Influenza B +1 more

COMPLETED

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04557046

Covid19

ACTIVE_NOT_RECRUITING NA

Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2

NCT03012217

Upper Resp Tract Infection

COMPLETED

Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.

NCT05765838

Influenza COVID-19 RSV Infection

UNKNOWN NA

A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test

NCT05331976

COVID-19 Asymptomatic COVID-19

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, non-randomized, observational, post-market, multicenter, clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection for evaluating the clinical performance of ClariLight Influenza A/B \& SARS-CoV-2 Cartridge and the ClariLight Influenza A/B \& RSV Cartridge by comparing them against a reference standard of care, CE marked, comparator device.

This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

This clinical performance study:

1. Does not involve surgically invasive sample-taking
2. Is not interventional as test results will not influence patient management decisions neither they will be used to guide treatment
3. There are no additional invasive procedures or other risks for the subjects. The device is being used within the scope of its CE marked intended purpose and for the specimen types claimed which include standard of care specimen collection procedures.

No specific follow-up of subjects providing swabs is required following termination, temporary suspension or early termination of the study, or withdrawal of the subject's informed consent. The participation of each subject for the total duration of the study will amount to 1 hour, finishing the participation in day 1. Subjects will be provided with the Investigator's contact information and be instructed to contact the Investigator if they experience any complications from the specimen collection procedures within twenty-four (24) hours of the visit".

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV2 Infection Influenza A Influenza B Respiratory Syncytial Virus (RSV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Site 1. Laboratorio Central Health Diagnostics Quirónsalud

COVID-19/Flu A/Flu B/RSV Test Kit

Intervention Type DEVICE

The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.

Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.

This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

SIte 2. Hospital General Universitario Dr. Balmis de Alicante

COVID-19/Flu A/Flu B/RSV Test Kit

Intervention Type DEVICE

The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.

Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.

This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

Site 3. Hospital Universitario de Getafe

COVID-19/Flu A/Flu B/RSV Test Kit

Intervention Type DEVICE

The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.

Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.

This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19/Flu A/Flu B/RSV Test Kit

The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.

Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.

This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with suspected respiratory infection who have physical signs/symptoms, such as chills, fever, headache, myalgia, fatigue, nasal congestion, sore throat, and other symptoms.
2. Subjects able to provide anterior nasal swabs and oropharyngeal swabs for testing on the study device according to the instructions for use of that device.
3. Subjects able to provide comparator samples according to the instructions for use of the comparator device.
4. Subjects able to provide study and comparator samples within 24 hours to allow for a valid comparison.
5. Subjects or their legal guardians willing and able to provide written informed consent.

Exclusion Criteria

1. Subjects who have undergone anterior nasal, or oropharyngeal sampling within the past 30 minutes (i.e. a minimum wait of 30 minutes is required before collecting swabs for the study device if previous anterior nasal or oropharyngeal samples were collected from the same subject).
2. Subjects or their legal guardians unwilling and unable to provide informed consent.
3. Subjects who have had a nasal wash or aspirate procedure within the past 24 hours.
4. Women who are pregnant or currently breastfeeding.

Eligible Sex

ALL

Accepts Healthy Volunteers

No